1.-Munshi,NC Barlogue,B:”Role for high-dose therapy with autologous hematopoietic stem cell suport in Waldenstrom´s macroglobulinemia.Sem Oncol 30(2):282-5,2003. 2.-Garcia-Sanz,R y cols: “Waldenstrom´s macroglobulinaemia :presenting features and outcome in a series with 217 cases.”Br J Haematol 115(3):575-82,2001. 3.-Kyle,RA:”Manegement of patients with Multiple Myeloma :emphasizing the role of high – dose therapy .”Clin Lymphoma 2(1): 21-8,2001. 4.-Gertz ,MA Fonseca R,Rajkumar,SV:”Waldenstrom´s macroglobulinemia” Oncologist 5(1):63-7,2000. 5.-Dimopoulos,MA Y Alexanian,R:”Waldenstrom´s macroglobulinemia”Blood 83 :1452-59,1994. 6.- Facon ,T y cols:” Prognostic factors in Waldenstrom´s macroglobulinemia : a report of 167 cases .”Journal of Clinical Oncology11:1553-58,1993. 7.- Gabbi,PG y cols:” Study of prognosis in Waldenstrom´s macroglobulinemia a proposal for simple binary classification with clinical and investigational utility.”Blood 83 :2939-45,1994. 8.-Kyle,RA y Gaston,JP: “The spectrum of IgMmonoclonal gammapathy in 430 cases .” Mayo Clin Proceedings 62:719-31,1987. 9.-Morel,P y cols:”Prognostic factors in Waldenstrom´s macroglobulinemiaa ,a report on 232 patients with the description of a new scoring system and its validation on 253 others patients.”Blood 96:852-58,2000. 10.- Díaz Maqueo,JC:”Diagnóstico erróneo de Mieloma Múltiple”.Rev Med IMSS 38(5):341.7,2000. 11.-Dimopoulos ,MA Galani,E Matsouka,C :”Waldenstroom’s macroglobulinemia”Hematol Oncol Clin North Am 13(6):1351-66,1999. 12.- Leith,D y cols:”Dysregulation of apoptosis in Wldenstrom’s macroglobulinemia does not involve nuclear factor Kappa B activation”Semin Oncol 30(2). 161-4,2003.
|